Roman, a US-based end-to-end healthcare product provider backed by media company Forbes, has rebranded to Ro and disclosed an $88m series A round led by venture capital firm FirstMark Capital.
VC firms Initialized Capital, General Catalyst, Slow Ventures, Sinai Ventures and Tusk Ventures, VC funds Torch Capital and BoxGroup, and unnamed angel investors also participated in the round.
Founded in 2017, Ro’s lead product is Roman, an online platform that enables users suffering from erectile dysfunction to get medication prescribed for the condition that is then delivered to their door each month.
The series A funding was disclosed alongside the launch of Zero, a service that assesses a user’s medical and smoking history. Once a physician has approved the request, the company will ship one of its Quit Kits to the user’s door.
Zero kits consist of nicotine gum and a prescription medication called bupropion that helps reduce a user’s cravings. They are currently available for pre-order and Ro will begin shipping them at the start of next month.
The company had previously raised $3.1m in a November 2017 seed round led by General Catalyst that included Forbes, Initialized Capital, BoxGroup, Slow Ventures and assorted angel investors.
Rick Heitzmann, managing director of FirstMark, will join the company’s board of directors in connection with the funding, along with Alexis Ohanian, a co-founder and general partner of Initialized Capital.
– Image courtesy of Ro.